The SP1-SuperEnhancer-SPHK1 Axis Mediates Niraparib Resistance in TNBC
<b>Background</b>: PARP inhibitors exhibit significant lethality in tumors with BRCA1/2 mutations or homologous recombination defects; however, their clinical application is limited by the rarity of BRCA1/2 mutations, complex resistance mechanisms, and limited efficacy of monotherapy. <b>Objective</...
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI AG
2025-10-01
|
| Sarja: | Pharmaceuticals |
| Aiheet: | |
| Linkit: | https://www.mdpi.com/1424-8247/18/11/1622 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|